Status:
COMPLETED
Newly Diagnosed Mature B-ALL, Burkitt's Lymphoma and Other High-grade Lymphoma in Adults
Lead Sponsor:
Nicola Goekbuget
Conditions:
Burkitt's Lymphoma
Burkitt's Leukemia
Eligibility:
All Genders
15-65 years
Phase:
PHASE4
Brief Summary
The study evaluates the efficacy and tolerability of alternating short cycles of high-dose and conventional chemotherapy in combination with rituximab in CD20 positive patients, followed by local radi...
Eligibility Criteria
Inclusion
- Burkitt's leukemia or Burkitt's lymphoma or primary mediastinal large B-cell lymphoma or B-precursor lymphoblastic lymphoma or large cell anaplastic lymphoma
- Age \> 15 years
- Written informed consent
Exclusion
- Serious secondary diseases, including psychiatric conditions, under which the required therapy compliance is not to be expected
- HIV infection
- Secondary lymphoma following prior chemotherapy/radiotherapy or active second malignancy
- Known severe allergy to foreign proteins
- Pre-treatment other than 1 cycle CHOP or similar; \< 1 week of another chemotherapy.
- Pregnancy or nursing
- Participation in other studies that interfere with study therapy
Key Trial Info
Start Date :
July 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2010
Estimated Enrollment :
650 Patients enrolled
Trial Details
Trial ID
NCT00199082
Start Date
July 1 2002
End Date
June 1 2010
Last Update
August 19 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital, Medical Dept. II
Frankfurt, Germany, 60590